Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone in Children With Refractory Cushing's Disease
NCT01925092Phase 3Withdrawn
- Sponsor
- Corcept Therapeutics
- Start
- Aug 2013
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of mifepristone in Cushing's disease (CD), sponsored by Corcept Therapeutics. Planned start Aug 2013; status: withdrawn.
02
Drugs
mifepristone
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT01925092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01925092.